for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

TAKARA BIO INC.

4974.T

Latest Trade

2,732.00JPY

Change

-50.00(-1.80%)

Volume

169,400

Today's Range

2,727.00

 - 

2,778.00

52 Week Range

2,671.00

 - 

3,340.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,782.00
Open
2,776.00
Volume
169,400
3M AVG Volume
4.64
Today's High
2,778.00
Today's Low
2,727.00
52 Week High
3,340.00
52 Week Low
2,671.00
Shares Out (MIL)
120.42
Market Cap (MIL)
334,996.20
Forward P/E
34.27
Dividend (Yield %)
0.58

Next Event

Q1 2022 Takara Bio Inc Earnings Release

Latest Developments

More

Takara Bio signs agreement for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies

Takara Bio say first patient enrolled into phase I clinical trial of Oncolytic Virus HF10 in Japan

Takara Holdings' subsidiary Takara Bio says merger between US-based units

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About TAKARA BIO INC.

TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.

Industry

Biotechnology & Drugs

Contact Info

7-4-38, Noji-Higashi

KUSATSU-SHI, SHG

525-0058

Japan

+81.77.5656920

http://www.takara-bio.co.jp

Executive Leadership

Hisashi Ohmiya

Chairman of the Board, Chairman of Subsidiary

Koichi Nakao

President, Executive President, President of Subsidiary, Representative Director

Shuichiro Matsuzaki

Vice President, Chief Financial Officer, Executive Vice President, Representative Director

Junichi Mineno

Chief Operating Officer, Senior Managing Executive Officer, Director

Tsuyoshi Miyamura

Managing Executive Officer, Chief Director of Sales, Director

Key Stats

2.43 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2019

0.0K

2020

0.0K

2021

0.0K

2022(E)

0.0K
EPS (JPY)

2019

30.380

2020

31.720

2021

79.290

2022(E)

81.184
Price To Earnings (TTM)
35.09
Price To Sales (TTM)
7.27
Price To Book (MRQ)
4.52
Price To Cash Flow (TTM)
25.21
Total Debt To Equity (MRQ)
1.54
LT Debt To Equity (MRQ)
1.35
Return on Investment (TTM)
13.21
Return on Equity (TTM)
11.63

Latest News

Latest News

BRIEF-Takara Bio Selects AGC Biologics As Manufacturer Of Plasmid DNA Intermediate For A Vaccine Against COVID-19

* TAKARA BIO SELECTS AGC BIOLOGICS AS MANUFACTURER OF PLASMID DNA INTERMEDIATE FOR A VACCINE AGAINST COVID-19 (SARS-COV-2)

BRIEF-Tasly Pharmaceutical's Unit Signs C-REV License Agreement With Japan's Takara Bio

* SAYS ITS UNIT OBTAINS EXCLUSIVE RIGHT IN CHINA TO PRODUCE AND COMMERCIALIZE PANCREATIC CANCER AND MELANOMA TREATMENT C-REVENUE DEVELOPED BY JAPAN'S TAKARA BIO Source text in Chinese: https://bit.ly/3drHhrk Further company coverage: (Reporting by Hong Kong newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up